
    
      In this 2-year, randomized, double-masked, multicenter, active controlled study, consenting
      patients will be randomized in a 1:1:1 ratio to one of the three treatment arms (Brolucizumab
      3 mg, Brolucizumab 6 mg, or Aflibercept 2 mg) and attend 28 planned visits.
    
  